# Gemini 3.1 Pro Preview / inf-d03

Original final answer, shared by both scoring rounds.

**Recommended Next Action**
Implement a hierarchical and pseudobulk-based analysis protocol that strictly defines the donor or animal as the independent experimental unit, rather than the individual cell or field. Because treating dependent cell-level observations as independent causes pseudoreplication, the proposed protocol uses a mixed-effects modeling approach (hierarchical) or aggregation (pseudobulk) to properly estimate uncertainty. To ensure robustness and calibrate unknown variance parameters, execute a proposed pilot calibration phase to estimate intraclass correlation (ICC), followed by grouped resampling, null calibration, and donor-level held-out validation in the main experiment. 

*Note: All experiments and analyses described herein are proposed.*

### Scientific Argument
**Evidence-to-Inference-to-Conclusion Chain:**
1. **Evidence:** The evidence defines pseudoreplication as inference that treats treatment subsamples or dependent observations as independent replication. 
2. **Inference:** Because treatments are assigned to donors/animals but measurements are taken at the cell/field level, analyzing cells as independent replicates would artificially inflate the degrees of freedom (pseudoreplication) and underestimate variance, leading to false-positive conclusions.
3. **Evidence:** The randomized treatment level defines the experimental unit, whereas observational and biological units can differ.
4. **Inference:** The donor/animal is the experimental unit. The cell/field is the observational unit. Inference must distinguish donor-level treatment effects from cell-level observational variance. 
5. **Evidence:** Clustering may alter uncertainty without changing a point estimate; very small independent *n* affects precision and robustness but does not automatically invalidate every model-based test; and high intraclass correlation (ICC) or loss of significance alone does not prove a false biological effect.
6. **Conclusion:** The proposed protocol must calculate point estimates and uncertainties by accounting for the clustered nature of the data (using hierarchical or pseudobulk comparisons). Because exact donor numbers, cell numbers, effect sizes, and variance components are unavailable, the protocol must begin with a calibration phase to determine ICC and properly size the donor *n*, ensuring that the statistical models correctly partition variance without prematurely discarding biological effects due to high ICC.

### Proposed Operational Protocol

#### 1. Preparation and Quality Checks
*   **Objective:** Calibrate unknown parameters (exact donor numbers, cell numbers, effect sizes, and variance components) before the main trial.
*   **Proposed Action:** Conduct a small-scale pilot experiment (e.g., control vs. treatment using a minimal available subset of donors). 
*   **Calibration Procedure:** Measure the cells/fields per donor and calculate the Intraclass Correlation Coefficient (ICC). The ICC will quantify the proportion of total variance attributable to donor-to-donor differences versus cell-to-cell differences. Use these calibrated variance components and the observed pilot effect size to power the main proposed study, determining the minimum number of experimental units (donors) needed to achieve statistical power at the donor level.
*   **Quality Check:** Confirm that cell viability, field focus, and assay quality metrics meet predefined thresholds before entering the data into the models.

#### 2. Independent Units
*   **Experimental Unit:** The individual donor or animal (the level at which the treatment is randomized).
*   **Observational Unit:** The individual cell or microscopic field (the level at which the assay is measured).
*   **Rule:** Analysis of treatment efficacy must be conducted or aggregated at the level of the independent experimental unit (the donor/animal).

#### 3. Allocation / Blinding
*   **Allocation:** Randomly assign donors/animals to the treatment or control groups using a random number generator. Ensure balance in donor-level covariates (e.g., age, sex) if applicable.
*   **Blinding:** Mask the treatment assignment labels. The personnel conducting the cell/field extractions, performing the assays, and running the initial data processing must be blind to whether a donor received the active treatment or control. 

#### 4. Intervention and Sampling
*   **Intervention:** Administer the assigned treatment or control condition to the intact donor/animal.
*   **Sampling:** Following the defined biological window, extract the relevant tissue from each donor and process it into single-cell suspensions or mount it for field-of-view microscopy. Extract multiple observational units (cells/fields) per donor.

#### 5. Measurements
*   Capture the dependent variables at the cell or field level (e.g., fluorescence intensity, transcript counts, morphological features). 
*   Tag every measurement with a unique identifier linking the observational unit (cell/field) to its specific experimental unit (donor/animal). 

#### 6. Controls
*   **Biological Controls:** Administer a vehicle/sham to the control group of donors to account for handling and administration effects.
*   **Technical Controls:** Standardize the cell/field measurement assays (e.g., background fluorescence correction, baseline calibration) to minimize technical variance between processing batches.

#### 7. Proposed Analysis
The proposed analysis pipeline strictly separates cell-level variance from donor-level inference through the following steps:

*   **Step 7a: Reporting of Unit Counts:** 
    Explicitly report both the randomized-unit counts (e.g., $N_{donors} = X$) and the observed-cell counts (e.g., $n_{cells} = Y$). This ensures transparency regarding the degrees of freedom used for statistical testing.
*   **Step 7b: Pseudobulk Comparison:** 
    Aggregate the cell/field-level measurements for each donor (e.g., using the mean or median of the cells within a donor) to create a single "pseudobulk" profile per donor. Conduct a standard hypothesis test (e.g., t-test or non-parametric equivalent) on these aggregated donor-level values to estimate the treatment effect.
*   **Step 7c: Hierarchical Comparison:** 
    Fit a mixed-effects regression model to the unaggregated cell-level data. Model the treatment as a fixed effect and the donor identifier as a random intercept (and random slope, if applicable). This utilizes all observational data while penalizing the degrees of freedom to reflect the true experimental *N*, adjusting the uncertainty based on the clustering.
*   **Step 7d: Grouped Resampling (Bootstrapping):** 
    To estimate the confidence intervals of the treatment effect robustly, perform bootstrap resampling at the *group level* (resample donors with replacement), rather than the cell level. Once a donor is selected, all of its constituent cells are included in that bootstrap iteration. 
*   **Step 7e: Null Calibration:** 
    Permute the treatment assignment labels strictly at the donor level (do not shuffle cells between donors). Re-run the pseudobulk and hierarchical models on these permuted datasets thousands of times to establish the empirical null distribution. Compare the observed test statistic against this null distribution to calibrate the false positive rate and confirm that the *p*-value is not artificially inflated by structural artifacts.
*   **Step 7f: Held-out Validation:** 
    Split the donors randomly into a training set and a held-out test set. Fit the hierarchical model on the training donors to estimate the expected effect size and variance. Apply this fitted model to the held-out validation donors to evaluate whether the observed biological effect generalizes to independent experimental units.

#### 8. Acceptance/Stopping Criteria
*   **Acceptance:** The study is accepted as valid if the null calibration yields an expected uniform distribution of *p*-values under the null, demonstrating that the false positive rate is controlled at the donor level. 
*   **Stopping Criteria:** The experiment will conclude when the pre-calibrated number of independent donors has been treated and measured. Sequential stopping based on cell-level significance must be strictly prohibited to prevent p-hacking.

#### 9. Troubleshooting and Limitations
*   **Consequential Uncertainty - Small Independent *n*:** If the final available number of donors is very small, pseudobulk comparisons may lack statistical power. However, per the evidence, a very small independent *n* affects precision and robustness but *does not automatically invalidate every model-based test*. The hierarchical model will remain structurally valid, though confidence intervals will widen. 
*   **Consequential Uncertainty - High Intraclass Correlation (ICC):** If the calibration or final analysis reveals high ICC (cells within a donor are highly similar, but donors vary wildly), the effective sample size approaches the donor *n*, and cell-level replication adds little statistical power. Per the evidence, high ICC or a subsequent loss of statistical significance does *not* prove a false biological effect; it indicates that the biological effect is masked by high donor variance. In this scenario, future iterations of the protocol should prioritize increasing donor *N* rather than measuring more cells per donor.
*   **Changes to the Recommendation:** If the calibration phase demonstrates an ICC precisely equal to zero (meaning donor identity contributes no variance whatsoever to the measurement), a standard unpooled analysis might theoretically be unbiased. However, conservative grouped analysis (hierarchical modeling) is still recommended as it will naturally reduce to the unpooled result if donor variance is zero, preventing any accidental pseudoreplication.
